查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363084

大肠直肠癌治疗药物市场规模、份额和趋势分析报告：按药物类别、地区和细分市场预测，2023-2030年

Colorectal Cancer Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Chemotherapy, Immunotherapy), By Region (North America, Asia Pacific, Latin America, Europe), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

大肠直肠癌治疗药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球大肠癌治疗市场规模将达到167亿美元，2023年至2030年年复合成长率为4.7%。

预计有几个要素将推动市场成长，例如增加目标人口和增加标靶治疗的采用。

正在研发的产品旨在满足大肠直肠癌 (CRC) 市场中一些未满足的需求。如果核准，Array Biopharma 的西妥昔单抗和 encorafenib联合治疗将成为第一个用于治疗 BRAF 突变 mCRC 的疗法。 Sumitomo Dainippon Pharma 的 napabucasin 是一种针对 STAT-3 的癌症干细胞抑制剂。

可切除的高危险性大肠直肠癌的辅助/新辅助治疗很少。在这种情况下，管道药物的缺乏是开发有效治疗方法的绝佳机会，可以提高切除患者的治癒率。目前，大多数可切除大肠直肠癌的可用治疗方法都是廉价的化疗方案和仿製药。

随着罗氏的阿瓦斯汀、安进的 Vectibix 和赛诺菲的 Zaltrap 等主要产品的专利到期，生物相似药预计将变得更加普遍。安进/艾尔建 (Amgen/Allergan) 的 Mvasi 是第一个于 2017 年在美国获得核准、于 2018 年在欧洲获得批准的阿瓦斯汀生物仿製药。 Cizumab 和 Claveva 是在印度推出的 Avastin 生物相似药之一。其他几种阿瓦斯汀和爱必妥生物仿製药正在开发中。

大肠直肠癌治疗药物市场报告亮点

  • 由于阿瓦斯汀 (Avastin) 和爱必妥 (Erbitux) 等标靶治疗的采用增加，到 2022 年，免疫疗法将在药物类别市场中占据主导地位。
  • 由于非特异性、副作用和抗药性的开拓，化疗可能会失去市场占有率。然而，随着最近Opdivo和Keytruda等抗PD1药物的上市及其针对性的作用机制，目前的情况可能会改变。
  • 按国家划分，美国拥有最大的市场份额，由于疾病负担增加、治疗率上升和药物成本急剧上升，预计到 2022 年将保持主导地位。
  • 由于阿瓦斯汀的使用量增加，2022 年罗氏在大肠癌产业中处于领先地位。阿瓦斯汀是 2022 年销售额最高的大肠直肠癌药物。然而，由于阿瓦斯汀的专利到期和生物相似药的渗透，罗氏预计将失去市场占有率。
  • 在 Opdivo 和 Keytruda 等标靶治疗的采用增加的推动下，百时美施贵宝和默克预计到 2022 年将成为结直肠癌药物市场的市场领导者。

目录

第1章调查方法和范围

第2章执行摘要

第3章大肠直肠癌治疗药物市场的变数、趋势和范围

  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 普及和成长预测图
  • 市场动态
    • 市场促进因素分析
    • 市场抑制因素分析
  • 大肠直肠癌治疗药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章结直肠癌治疗药物市场：按药物类别估计和趋势分析

  • 大肠直肠癌药物市场：重点
  • 大肠直肠癌药物市场：2022 年和 2030 年趋势和市场占有率分析
  • 化疗
  • 免疫疗法
  • 其他的

第5章结直肠癌治疗药物市场：区域估计和趋势分析

  • 区域预测
  • 按地区分類的结直肠癌药物市场：要点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第6章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • Amgen, Inc.
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Lilly
    • Merck & co., Inc.
    • F. Hoffmann-La Roche Ltd
    • Sanofi
Product Code: GVR-2-68038-512-0

Colorectal Cancer Therapeutics Market Growth & Trends:

The global colorectal cancer therapeutics market size is expected to reach USD 16.7 billion by 2030, according to a new report by Grand View Research, Inc.., exhibiting a CAGR of 4.7% from 2023 to 2030. Several factors such as increasing target population and rising adoption of targeted therapies are anticipated to fuel market growth.

Products in the pipeline are striving to meet some of the unmet needs of the colorectal cancer (CRC) market. If approved, Array Biopharma's cetuximab plus encorafenib would become the first therapy indicated for BRAF-mutant mCRC treatment. Sumitomo Dainippon's Napabucasin is a cancer stem cell inhibitor targeting STAT-3.

There are few available adjuvant/neoadjuvant medicines for treatment of high-risk resectable colorectal cancer. Lack of pipeline agents in this setting presents a good opportunity for development of effective treatments that can improve cure rates for resected patients. At present, most available treatments for resectable CRC include cheaper chemotherapeutic regimens and generics.

Upcoming patent expiries of key products such as Roche's Avastin, Amgen's Vectibix, and Sanofi's Zaltrap will lead to biosimilar penetration. Amgen/Allergan's Mvasi marked the first Avastin biosimilar approval in U.S. and Europe in 2017 and 2018, respectively. Cizumab and Krabeva are some of the biosimilars to Avastin launched in India. Several other biosimilars to Avastin and Erbitux are under development.

Colorectal Cancer Therapeutics Market Report Highlights:

  • Immunotherapy dominated the market based on drug class in 2022, owing to increasing adoption of targeted therapies such as Avastin and Erbitux
  • Chemotherapy is likely to lose market share on account of non-specificity, adverse effects, and development of resistance to chemical agents. However, recent launch of anti-PD1 drugs such as Opdivo and Keytruda is likely to change the current landscape due to their target-oriented mechanism of action
  • U.S. accounted for the largest share based on country and is projected to maintain its dominance through to 2022 owing to growing disease burden, increasing treatment rate, and high cost of drugs
  • Roche led the colorectal cancer industrial setting in 2022 due to growing usage of Avastin. Avastin was the highest revenue-generating CRC medicine in 2022. However, Roche is projected to lose market share on grounds of Avastin's patent expiry and biosimilar penetration
  • Bristol-Myer Squibb and Merck are anticipated to be market leaders in the colorectal cancer drugs market space by 2022 due to increasing adoption of targeted therapies such as Opdivo and Keytruda.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug class
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Colorectal Cancer Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Colorectal Cancer Therapeutics Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic Landscape

Chapter 4. Colorectal Cancer Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Colorectal Cancer Therapeutics Market: Key Takeaways
  • 4.2. Colorectal Cancer Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Chemotherapy
    • 4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Immunotherapy
    • 4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Colorectal Cancer Therapeutics Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Outlook
  • 5.2. Colorectal Cancer Therapeutics Market by Region: Key Takeaway
  • 5.3. North America
    • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.3. France
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.6. Denmark
      • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.7. Sweden
      • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.8. Norway
      • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.2. China
      • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.3. India
      • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.5. Thailand
      • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.6. South Korea
      • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.2. Mexico
      • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7. MEA
    • 5.7.1. South Africa
      • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.2. Saudi Arabia
      • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Market Participant Categorization
    • 6.2.1. Amgen, Inc.
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Financial performance
      • 6.2.1.3. Product benchmarking
      • 6.2.1.4. Strategic initiatives
    • 6.2.2. Bayer AG
      • 6.2.2.1. Company overview
      • 6.2.2.2. Financial performance
      • 6.2.2.3. Product benchmarking
      • 6.2.2.4. Strategic initiatives
    • 6.2.3. Bristol-Myers Squibb Company
      • 6.2.3.1. Company overview
      • 6.2.3.2. Financial performance
      • 6.2.3.3. Product benchmarking
      • 6.2.3.4. Strategic initiatives
    • 6.2.4. Lilly
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. Merck & co., Inc.
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. F. Hoffmann-La Roche Ltd
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. Sanofi
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 3 North America colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 4 U.S. colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 Canada colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 6 Europe colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 Europe colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 8 Germany colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 UK colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 France colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 11 Italy colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 12 Spain colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 Sweden colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Norway colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 15 Denmark colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 18 Japan colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 China colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 20 India colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Australia colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Thailand colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 South Korea colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 24 Latin America colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 Latin America colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 26 Brazil colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Mexico colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 28 Argentina colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Middle East and Africa colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 30 Middle East and Africa colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 31 South Africa colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 33 UAE colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 Kuwait colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Colorectal cancer therapeutics: Market outlook
  • Fig. 9 Colorectal cancer therapeutics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Colorectal cancer therapeutics market driver impact
  • Fig. 15 Colorectal cancer therapeutics market restraint impact
  • Fig. 16 Colorectal cancer Therapeutics market strategic Initiatives analysis
  • Fig. 17 Colorectal cancer therapeutics market: Drug class movement analysis
  • Fig. 18 Colorectal cancer therapeutics market: Drug class outlook and key takeaways
  • Fig. 19 Immunotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Global Colorectal Cancer Therapeutics market: Regional Movement Analysis
  • Fig. 23 Global Colorectal cancer therapeutics market: Regional outlook and key takeaways
  • Fig. 24 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)